The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients or healthcare professionals.
ISOVUE® (Iopamidol Injection) Imaging Bulk Package is the first FDA-approved contrast medium designed for multidose use—multiple single doses for multiple patients in the computed tomography suite and angiography procedures.
How to Order
ISOVUE® (Iopamidol injection) Imaging Bulk Package
ISOVUE® -300* (Iopamidol Injection 61%) Imaging Bulk Package** |
|
|---|---|
| Description | NDC Number |
| Ten 200 mL bottles | 0270-1315-45 |
| Six 500 mL bottles | 0270-1315-95 |
ISOVUE® -370* (Iopamidol Injection 76%) Imaging Bulk Package** |
|
| Description | NDC Number |
| Ten 200 mL bottles | 0270-1316-45 |
| Six 500 mL bottles | 0270-1316-95 |
*Concentration (mg/mL)
**For use only with an automated contrast injection system or cleared for use with this contrast
To order, call Bracco:
1-877-BRACCO-9
(1-877-272-2269)
or visit us online at:
MyOrders.Bracco.com
The individuals who appear are for illustrative purposes. All persons depicted are models and not real healthcare professionals.
Reimbursement Support Information
Your one-stop resource for coding, reimbursement support, and education.
HCPCS Code
- ISOVUE Imaging Bulk Package should be coded under Q9967: LOCM 300-399mb/mL iodine, 1 mL.
CMS Hospital Outpatient Prospective Payment System
- Under HOPPS, reimbursement for ISOVUE Imaging Bulk Package is bundled in with the primary procedure and paid under the relevant Ambulatory Payment Classification. Please continue to include Q9967 on your charge master to assist CMS with future rate setting.
Medicare Physician Fee Schedule
- The MPFS is used in non-hospital sites including independent diagnostic testing facilities and physician offices
- Under MPFS, ISOVUE Imaging Bulk Package is separately reimbursable from the primary procedure. Reimbursement rates change on a quarterly basis and are including in the CMS ASP Pricing files
- Contrast agents are subject to the JW and JZ Modifiers under MPFS. Please use the JW Modifier to identify waste, and the JZ Modifier to indicate when there has been no waste.
Commercial Payors
- Commercial payors' policies and contracts can vary greatly across the country. Please check your individual agreements to find out how reimbursement for ISOVUE Imaging Bulk Package may impact your site.
Visit the Bracco Reimbursement Site
Research Library
Shrank W et al.
Waste in the US Health Care System: Estimated Costs and Potential for Savings
The CARE Study
Cardiac Angiography in Renally Impaired Patients (CARE) study: A randomized, double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease
Solomon R et al.
Contast-Induced Nephropathy and Long-Term Adverse Events: Cause and Effect?
Solomon R
How Much Contrast Media Can Be Used Safely in the Cardiac Catheterization Lab?
Disclaimers
The information provided is general reimbursement information for Bracco products. It is not legal advice, nor is it advice about how to code, complete or submit any particular claim for payment. Although we supply this information based on our current knowledge, it is always the provider’s responsibility to determine and submit appropriate codes, charges, modifiers and bills for services that were rendered. This coding and reimbursement information is subject to change without notice. Payers or their local branches may have their own coding and reimbursement requirements and policies. Before filing any claims, providers should verify current requirements and policies with the payer.
CPT® copyright 2024 American Medical Association (AMA). All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
IMPORTANT SAFETY INFORMATION
ISOVUE is for intra-arterial or intravenous use only.
WARNINGS AND PRECAUTIONS | Risks Associated with Intrathecal Administration
Intrathecal administration, even if inadvertent, can cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ISOVUE is for intra-arterial or intravenous use only and must not be administered intrathecally.
ISOVUE®-200, -250, -300, -370 (Iopamidol Injection)
ISOVUE®-300, -370 (Iopamidol Injection) Imaging Bulk Package is indicated for:
- angiography in adults throughout the cardiovascular system including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography
- in pediatric patients for angiocardiography
- in adult and pediatric intravenous excretory urography
- contrast enhancement of computed tomographic (CECT) head and body imaging
- peripheral venography in adults
ISOVUE®-200, -250, -300, -370 (Iopamidol Injection) is indicated for:
Oral procedures in pediatric patients and adults for:
- CT of the abdomen and pelvis to delineate the gastrointestinal tract in adults and pediatric patients
WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION
Intrathecal administration, even if inadvertent, can cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ISOVUE is for intra-arterial or intravenous use only.
IMPORTANT SAFETY INFORMATION:
WARNINGS AND PRECAUTIONS
Risks Associated with Intrathecal Administration
Intrathecal administration, even if inadvertent, can cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ISOVUE is for intra-arterial or intravenous use only and must not be administered intrathecally.
Hypersensitivity Reactions
ISOVUE can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.
Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock. Most severe reactions develop shortly after the start of injection (e.g., within 1 to 3 minutes), but delayed reactions can also occur. There is increased risk of hypersensitivity reactions in patients with a history of previous reactions to contrast agents, and allergic disorders (i.e., bronchial asthma, allergic rhinitis, and food allergies) or other hypersensitivities. Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to ISOVUE administration. Monitor all patients for hypersensitivity reactions.
Acute Kidney Injury
Acute kidney injury, including renal failure, may occur after ISOVUE administration. Risk factors include: pre-existing renal insufficiency, dehydration, diabetes mellitus, congestive heart failure, advanced vascular disease, elderly age, concomitant use of nephrotoxic or diuretic medications, multiple myeloma or other paraproteinemias, and repetitive or large doses of ISOVUE. Use the lowest necessary dose of ISOVUE in patients with renal impairment. Adequately hydrate patients prior to and following ISOVUE administration. Do not use laxatives, diuretics, or preparatorydehydration prior to ISOVUE administration.
Cardiovascular Adverse Reactions
ISOVUE increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, severely impaired renal function, combined renal and hepatic disease, and combined renal and cardiac disease, particularly when repetitive or large doses are administered. Fatal cardiovascular reactions have occurred mostly within 10 minutes of ISOVUE injection; the main feature was cardiac arrest with cardiovascular disease as the main underlying factor. Hypotensive collapse and shock have occurred. Cardiac decompensation, serious arrhythmias, and myocardial ischemia or infarction can occur during coronary arteriography and ventriculography. Use the lowest necessary dose of ISOVUE in patients with congestive heart failure and always have emergency resuscitation equipment and trained personnel available. Monitor all patients for severe cardiovascular reactions.
Thromboembolic Events
Serious, in some cases fatal, thromboembolic events, including myocardial infarction and stroke, can occur during angiographic procedures. During these procedures, increased thrombosis and activation of the complement system occurs. Risk factors for developing thromboembolic events include: length of procedure, catheter and syringe material, underlying disease state, and concomitant medications. To minimize thromboembolic events, usemeticulous angiographic techniques and minimize the length of the procedure. Avoid blood remaining in contact with syringes containing iodinated contrast agents, which increases risk of clotting. Avoid angiocardiography in patients with homocystinuria because of the risk of inducing thrombosis and embolism.
Extravasation and Injection Site Reactions
Extravasation can occur with ISOVUE administration, particularly in patients with severe arterial or venous disease. Inflammation, blistering, skin necrosis, and compartment syndrome have been reported following extravasation. In addition, injection site reactions such as pain and swelling at the injection site can also occur. Ensure intravascular placement of catheters prior to injection. Monitor patients for extravasation and advise patients to seek medical care for progression of symptoms.
Thyroid Storm in Patients with Hyperthyroidism
Thyroid storm has occurred after the intravascular use of iodinated agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule. Evaluate the risk in such patients before use of ISOVUE.
Thyroid Dysfunction in Pediatric Patients 0 Years to 3 Years of Age
Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast agents in pediatric patients 0 years to 3 years of age.Younger age, very low birth weight, prematurity, underlying medical conditions affecting thyroid function, admission to neonatal or pediatric intensive care units, and congenital cardiac conditions are associated with an increased risk of hypothyroidism after iodinated contrast agent exposure. Pediatric patients with congenital cardiac conditions may be at greatest risk given that they often require high doses of contrast during invasive cardiac procedures. An underactive thyroid during early life may be harmful for cognitive and neurological development and may require thyroid hormone replacement therapy. After exposure to iodinated contrast agents, individualize thyroid function monitoring based on underlying risk factors, especially in term and preterm neonates.
Hypertensive Crisis in Patients with Pheochromocytoma
Hypertensive crisis in patients with pheochromocytoma has occurred with iodinated contrast agents. Closely monitor patients when administering ISOVUE if pheochromocytoma or catecholamine-secreting7 of 13paragangliomas are suspected. Inject the minimum amount of ISOVUE necessary and have measures for treatment of hypertensive crisis readily available.
Severe Cutaneous Adverse Reactions
Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after intravascular contrast agent administration. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS). Reaction severity may increase and time to onset may decrease with repeat administration of a contrast agent; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions. Avoid administering ISOVUE to patients with a history of a severe cutaneous adverse reaction to ISOVUE.
Interference with Laboratory Tests
ISOVUE can interfere with protein-bound iodine test.
ADVERSE REACTIONS
The most frequent adverse reactions are pain, hot flashes, burning sensation, nausea, and warmth.
DRUG INTERACTIONS
Metformin: In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function.
Radioactive Iodine: Administration of ISOVUE may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post ISOVUE.
USE IN SPECIFIC POPULATIONS
Geriatric Use: Iopamidol is excreted by the kidney, and the risk of adverse reactions to ISOVUE may be greater in patients with renal impairment. Because patients 65 years of age and older are more likely to have renal impairment, care should be taken in dose selection, and it may be useful to monitor renal function.
Renal Impairment: The clearance of iopamidol decreases with increasing degree of renal impairment and results in delayed opacification of the urinary system. In addition, preexisting renal impairment increases the risk for acute kidney injury. Iopamidol can be removed by dialysis.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for full Prescribing Information for ISOVUE® products.
Please click here for full Prescribing Information for ISOVUE® Imaging Bulk Package products.
ISOVUE and ISOVUE Imaging Bulk Package are currently manufactured for Bracco Diagnostics Inc. at three locations: BIPSO GmbH, Singen (Germany), Patheon Italia S.p.A., Ferentino (Italy), and S. M. Farmaceutici SRL, Tito (Italy).
ISOVUE is a registered trademark of Bracco Diagnostics Inc.